Bioneer（A064550）株式概要ビオネア株式会社は、韓国、アメリカ大陸、ヨーロッパ、アジア、アフリカ、そして国際的にバイオテクノロジー企業として事業を展開している。 詳細A064550 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析過去5年間で収益は年間75.6%減少しました。 すべてのリスクチェックを見るA064550 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW483,546 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA483,546 investors already sharing narrativesYour Fair Value₩Current Price₩6.38k89.3% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-26b507b2016201920222025202620282031Revenue ₩507.2bEarnings ₩89.0bAdvancedSet Fair ValueView all narrativesBioneer Corporation 競合他社HLB TherapeuticsLtdSymbol: KOSDAQ:A115450Market cap: ₩160.2bBNC KOREASymbol: KOSDAQ:A256840Market cap: ₩164.1bAnterogen.Co.LtdSymbol: KOSDAQ:A065660Market cap: ₩160.6bS.BiomedicsSymbol: KOSDAQ:A304360Market cap: ₩209.9b価格と性能株価の高値、安値、推移の概要Bioneer過去の株価現在の株価₩6,380.0052週高値₩15,870.0052週安値₩5,870.00ベータ0.0861ヶ月の変化-3.48%3ヶ月変化-41.84%1年変化-58.97%3年間の変化-85.27%5年間の変化-82.73%IPOからの変化-54.10%最新ニュース分析記事 • Oct 31Bioneer (KOSDAQ:064550) Is Making Moderate Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Aug 30New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. This is currently the only risk that has been identified for the company.分析記事 • Jul 22Bioneer (KOSDAQ:064550) Is Making Moderate Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Apr 15Is Bioneer (KOSDAQ:064550) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Mar 24New major risk - Revenue and earnings growthEarnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.分析記事 • Mar 04Bioneer Corporation (KOSDAQ:064550) Not Doing Enough For Some Investors As Its Shares Slump 25%The Bioneer Corporation ( KOSDAQ:064550 ) share price has fared very poorly over the last month, falling by a...最新情報をもっと見るRecent updates分析記事 • Oct 31Bioneer (KOSDAQ:064550) Is Making Moderate Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Aug 30New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. This is currently the only risk that has been identified for the company.分析記事 • Jul 22Bioneer (KOSDAQ:064550) Is Making Moderate Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Apr 15Is Bioneer (KOSDAQ:064550) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Mar 24New major risk - Revenue and earnings growthEarnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.分析記事 • Mar 04Bioneer Corporation (KOSDAQ:064550) Not Doing Enough For Some Investors As Its Shares Slump 25%The Bioneer Corporation ( KOSDAQ:064550 ) share price has fared very poorly over the last month, falling by a...お知らせ • Mar 01Bioneer Corporation, Annual General Meeting, Mar 31, 2025Bioneer Corporation, Annual General Meeting, Mar 31, 2025, at 10:30 Tokyo Standard Time. Location: auditorium, 71, techno 2-ro, yuseong-gu, daejeon South KoreaNew Risk • Dec 09New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company.分析記事 • Nov 14Investors Don't See Light At End Of Bioneer Corporation's (KOSDAQ:064550) Tunnel And Push Stock Down 26%Unfortunately for some shareholders, the Bioneer Corporation ( KOSDAQ:064550 ) share price has dived 26% in the last...分析記事 • Sep 06Bioneer Corporation's (KOSDAQ:064550) 27% Dip In Price Shows Sentiment Is Matching RevenuesBioneer Corporation ( KOSDAQ:064550 ) shareholders won't be pleased to see that the share price has had a very rough...分析記事 • Jul 11Bioneer Corporation's (KOSDAQ:064550) Share Price Boosted 25% But Its Business Prospects Need A Lift TooDespite an already strong run, Bioneer Corporation ( KOSDAQ:064550 ) shares have been powering on, with a gain of 25...New Risk • Jul 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.6% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change).New Risk • May 25New major risk - Revenue and earnings growthEarnings have declined by 2.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.6% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.9% average weekly change).分析記事 • Mar 06Lacklustre Performance Is Driving Bioneer Corporation's (KOSDAQ:064550) Low P/SWith a price-to-sales (or "P/S") ratio of 3x Bioneer Corporation ( KOSDAQ:064550 ) may be sending very bullish signals...お知らせ • Mar 05Bioneer Corporation, Annual General Meeting, Mar 28, 2024Bioneer Corporation, Annual General Meeting, Mar 28, 2024, at 10:30 Korea Standard Time. Location: Auditorium in Bioneer's Global Center 71, Techno 2-ro, Yuseong-gu Daejeon South Korea Agenda: To consider audit and sales report; to consider report on the internal control over financial reporting operations; to consider approval of separate and consolidated financial statements for the 32nd fiscal year; to consider reappointment of Sangjoon kim as an outside director; to consider reappointment of Sanggyu kim as an outside director; to consider reappointment of Hanee park as an inside director; to consider reappointment of Jaeha kim as an inside director; to consider reappointment of Jinpyeong jeong as an inside director; to consider appointment of Joongyeol lee as a new inside director; to consider appointment of auditors; and to consider other issues.Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩18.00 (vs ₩335 in 3Q 2022)Third quarter 2023 results: EPS: ₩18.00 (down from ₩335 in 3Q 2022). Revenue: ₩73.7b (up 35% from 3Q 2022). Net income: ₩475.9m (down 95% from 3Q 2022). Profit margin: 0.6% (down from 16% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.Valuation Update With 7 Day Price Move • Mar 24Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩41,350, the stock trades at a trailing P/E ratio of 46x. Average forward P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 245% over the past three years.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩32,000, the stock trades at a trailing P/E ratio of 35.6x. Average forward P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 333% over the past three years.Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 48% share price gain to ₩34,150, the stock trades at a trailing P/E ratio of 42.6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 279% over the past three years.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩24,800, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 147% over the past three years.Valuation Update With 7 Day Price Move • Mar 02Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩40,000, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 342% over the past three years.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩36,350, the stock trades at a trailing P/E ratio of 16.5x. Average trailing P/E is 33x in the Biotechs industry in South Korea. Total returns to shareholders of 324% over the past three years.Valuation Update With 7 Day Price Move • Dec 28Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩47,000, the stock trades at a trailing P/E ratio of 21.3x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total returns to shareholders of 523% over the past three years.Valuation Update With 7 Day Price Move • Dec 01Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₩40,150, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total returns to shareholders of 351% over the past three years.Reported Earnings • Nov 16Third quarter 2021 earnings released: ₩386 loss per share (vs ₩116 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩64.0b (down 13% from 3Q 2020). Net loss: ₩9.74b (down 468% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 77% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Sep 29Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩71,500, the stock trades at a trailing P/E ratio of 26x. Average forward P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 571% over the past three years.Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩84,600, the stock trades at a trailing P/E ratio of 29.7x. Average forward P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 558% over the past three years.Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₩67,600, the stock trades at a trailing P/E ratio of 23.7x. Average forward P/E is 33x in the Biotechs industry in South Korea. Total returns to shareholders of 450% over the past three years.Valuation Update With 7 Day Price Move • Aug 09Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩40,400, the stock trades at a trailing P/E ratio of 10.2x. Average forward P/E is 29x in the Biotechs industry in South Korea. Total returns to shareholders of 296% over the past three years.Valuation Update With 7 Day Price Move • Jul 22Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩37,300, the stock trades at a trailing P/E ratio of 9.4x. Average forward P/E is 35x in the Biotechs industry in South Korea. Total returns to shareholders of 291% over the past three years.Valuation Update With 7 Day Price Move • Jul 03Investor sentiment improved over the past weekAfter last week's 33% share price gain to ₩26,400, the stock trades at a trailing P/E ratio of 6.7x. Average forward P/E is 36x in the Biotechs industry in South Korea. Total returns to shareholders of 188% over the past three years.分析記事 • Mar 25Bioneer (KOSDAQ:064550) Seems To Use Debt Quite SensiblyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩16,100, the stock is trading at a trailing P/E ratio of 18.2x, down from the previous P/E ratio of 21.4x. This compares to an average P/E of 54x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 36%.分析記事 • Feb 15Bioneer Corporation's (KOSDAQ:064550) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?It is hard to get excited after looking at Bioneer's (KOSDAQ:064550) recent performance, when its stock has declined...分析記事 • Jan 20Investors Who Bought Bioneer (KOSDAQ:064550) Shares A Year Ago Are Now Up 166%The last three months have been tough on Bioneer Corporation ( KOSDAQ:064550 ) shareholders, who have seen the share...Valuation Update With 7 Day Price Move • Jan 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩18,600, the stock is trading at a trailing P/E ratio of 21x, up from the previous P/E ratio of 18x. This compares to an average P/E of 57x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 90%.Valuation Update With 7 Day Price Move • Dec 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩16,000, the stock is trading at a trailing P/E ratio of 18x, down from the previous P/E ratio of 21.4x. This compares to an average P/E of 55x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 78%.分析記事 • Dec 24Is Bioneer (KOSDAQ:064550) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is New 90 Day High Low • Dec 22New 90-day low: ₩17,650The company is down 33% from its price of ₩26,450 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 14% over the same period.分析記事 • Nov 28Here's Why We Think Bioneer's (KOSDAQ:064550) Statutory Earnings Might Be ConservativeIt might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...Is New 90 Day High Low • Nov 12New 90-day low: ₩21,100The company is down 1.0% from its price of ₩21,300 on 14 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 4.0% over the same period.Valuation Update With 7 Day Price Move • Nov 12Market pulls back on stock over the past weekAfter last week's 19% share price decline to ₩21,100, the stock is trading at a trailing P/E ratio of 29.7x, down from the previous P/E ratio of 36.7x. This compares to an average P/E of 69x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 153%.Valuation Update With 7 Day Price Move • Oct 28Market pulls back on stock over the past weekAfter last week's 16% share price decline to ₩22,450, the stock is trading at a trailing P/E ratio of 31.6x, down from the previous P/E ratio of 37.8x. This compares to an average P/E of 58x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 172%.株主還元A064550KR BiotechsKR 市場7D2.9%-4.4%-2.3%1Y-59.0%-14.5%97.1%株主還元を見る業界別リターン: A064550過去 1 年間で-14.5 % の収益を上げたKR Biotechs業界を下回りました。リターン対市場: A064550は、過去 1 年間で97.1 % のリターンを上げたKR市場を下回りました。価格変動Is A064550's price volatile compared to industry and market?A064550 volatilityA064550 Average Weekly Movement9.5%Biotechs Industry Average Movement11.5%Market Average Movement9.5%10% most volatile stocks in KR Market17.1%10% least volatile stocks in KR Market5.0%安定した株価: A064550 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A064550の 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1992392Han-Oh Parkwww.bioneer.co.krビオネア株式会社は、韓国、米州、欧州、アジア、アフリカ、および国際的なバイオテクノロジー企業として事業を展開している。同社は、PCRおよびRT-PCR、リアルタイムPCR、RNAi、化学薬品、プラスチック消耗品、緩衝液および溶液、ならびにサンプル調製、タンパク質合成および精製、遺伝子クローニング、蛍光色素およびクエンチャー、電気泳動、ゲノムワイド機能、磁気分離サービス、ならびにコンベンショナルPCR、リアルタイムPCR、サンプル調製、タンパク質合成、遠心分離機およびボルテックスミキサー、電気泳動用の機器を提供している。また、MDx技術、ヒト診断キット、MDx抽出キット、器具を含む分子診断、動物、水生生物、蚊媒介、植物病、食品安全、ヒト病原体、ナノバイオ製品などの製品も提供している。同社は1992年に設立され、韓国のテジョンに本社を置いている。もっと見るBioneer Corporation 基礎のまとめBioneer の収益と売上を時価総額と比較するとどうか。A064550 基礎統計学時価総額₩164.67b収益（TTM）-₩5.84b売上高(TTM)₩338.01b0.5xP/Sレシオ-28.2xPER（株価収益率A064550 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A064550 損益計算書（TTM）収益₩338.01b売上原価₩76.70b売上総利益₩261.31bその他の費用₩267.15b収益-₩5.84b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-226.16グロス・マージン77.31%純利益率-1.73%有利子負債／自己資本比率48.1%A064550 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/25 19:46終値2026/07/24 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioneer Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Ji-woo BaekShinhan Investment Corp.Choongwoo SeoSK Securities Co., Ltd.Mihwa SeoYuanta Securities Korea Co., Ltd.
分析記事 • Oct 31Bioneer (KOSDAQ:064550) Is Making Moderate Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Aug 30New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. This is currently the only risk that has been identified for the company.
分析記事 • Jul 22Bioneer (KOSDAQ:064550) Is Making Moderate Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Apr 15Is Bioneer (KOSDAQ:064550) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Mar 24New major risk - Revenue and earnings growthEarnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
分析記事 • Mar 04Bioneer Corporation (KOSDAQ:064550) Not Doing Enough For Some Investors As Its Shares Slump 25%The Bioneer Corporation ( KOSDAQ:064550 ) share price has fared very poorly over the last month, falling by a...
分析記事 • Oct 31Bioneer (KOSDAQ:064550) Is Making Moderate Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Aug 30New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. This is currently the only risk that has been identified for the company.
分析記事 • Jul 22Bioneer (KOSDAQ:064550) Is Making Moderate Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Apr 15Is Bioneer (KOSDAQ:064550) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Mar 24New major risk - Revenue and earnings growthEarnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
分析記事 • Mar 04Bioneer Corporation (KOSDAQ:064550) Not Doing Enough For Some Investors As Its Shares Slump 25%The Bioneer Corporation ( KOSDAQ:064550 ) share price has fared very poorly over the last month, falling by a...
お知らせ • Mar 01Bioneer Corporation, Annual General Meeting, Mar 31, 2025Bioneer Corporation, Annual General Meeting, Mar 31, 2025, at 10:30 Tokyo Standard Time. Location: auditorium, 71, techno 2-ro, yuseong-gu, daejeon South Korea
New Risk • Dec 09New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company.
分析記事 • Nov 14Investors Don't See Light At End Of Bioneer Corporation's (KOSDAQ:064550) Tunnel And Push Stock Down 26%Unfortunately for some shareholders, the Bioneer Corporation ( KOSDAQ:064550 ) share price has dived 26% in the last...
分析記事 • Sep 06Bioneer Corporation's (KOSDAQ:064550) 27% Dip In Price Shows Sentiment Is Matching RevenuesBioneer Corporation ( KOSDAQ:064550 ) shareholders won't be pleased to see that the share price has had a very rough...
分析記事 • Jul 11Bioneer Corporation's (KOSDAQ:064550) Share Price Boosted 25% But Its Business Prospects Need A Lift TooDespite an already strong run, Bioneer Corporation ( KOSDAQ:064550 ) shares have been powering on, with a gain of 25...
New Risk • Jul 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.6% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change).
New Risk • May 25New major risk - Revenue and earnings growthEarnings have declined by 2.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.6% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.9% average weekly change).
分析記事 • Mar 06Lacklustre Performance Is Driving Bioneer Corporation's (KOSDAQ:064550) Low P/SWith a price-to-sales (or "P/S") ratio of 3x Bioneer Corporation ( KOSDAQ:064550 ) may be sending very bullish signals...
お知らせ • Mar 05Bioneer Corporation, Annual General Meeting, Mar 28, 2024Bioneer Corporation, Annual General Meeting, Mar 28, 2024, at 10:30 Korea Standard Time. Location: Auditorium in Bioneer's Global Center 71, Techno 2-ro, Yuseong-gu Daejeon South Korea Agenda: To consider audit and sales report; to consider report on the internal control over financial reporting operations; to consider approval of separate and consolidated financial statements for the 32nd fiscal year; to consider reappointment of Sangjoon kim as an outside director; to consider reappointment of Sanggyu kim as an outside director; to consider reappointment of Hanee park as an inside director; to consider reappointment of Jaeha kim as an inside director; to consider reappointment of Jinpyeong jeong as an inside director; to consider appointment of Joongyeol lee as a new inside director; to consider appointment of auditors; and to consider other issues.
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩18.00 (vs ₩335 in 3Q 2022)Third quarter 2023 results: EPS: ₩18.00 (down from ₩335 in 3Q 2022). Revenue: ₩73.7b (up 35% from 3Q 2022). Net income: ₩475.9m (down 95% from 3Q 2022). Profit margin: 0.6% (down from 16% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
Valuation Update With 7 Day Price Move • Mar 24Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩41,350, the stock trades at a trailing P/E ratio of 46x. Average forward P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 245% over the past three years.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩32,000, the stock trades at a trailing P/E ratio of 35.6x. Average forward P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 333% over the past three years.
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 48% share price gain to ₩34,150, the stock trades at a trailing P/E ratio of 42.6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 279% over the past three years.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩24,800, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 147% over the past three years.
Valuation Update With 7 Day Price Move • Mar 02Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩40,000, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 342% over the past three years.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩36,350, the stock trades at a trailing P/E ratio of 16.5x. Average trailing P/E is 33x in the Biotechs industry in South Korea. Total returns to shareholders of 324% over the past three years.
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩47,000, the stock trades at a trailing P/E ratio of 21.3x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total returns to shareholders of 523% over the past three years.
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₩40,150, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total returns to shareholders of 351% over the past three years.
Reported Earnings • Nov 16Third quarter 2021 earnings released: ₩386 loss per share (vs ₩116 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩64.0b (down 13% from 3Q 2020). Net loss: ₩9.74b (down 468% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 77% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Sep 29Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩71,500, the stock trades at a trailing P/E ratio of 26x. Average forward P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 571% over the past three years.
Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩84,600, the stock trades at a trailing P/E ratio of 29.7x. Average forward P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 558% over the past three years.
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₩67,600, the stock trades at a trailing P/E ratio of 23.7x. Average forward P/E is 33x in the Biotechs industry in South Korea. Total returns to shareholders of 450% over the past three years.
Valuation Update With 7 Day Price Move • Aug 09Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩40,400, the stock trades at a trailing P/E ratio of 10.2x. Average forward P/E is 29x in the Biotechs industry in South Korea. Total returns to shareholders of 296% over the past three years.
Valuation Update With 7 Day Price Move • Jul 22Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩37,300, the stock trades at a trailing P/E ratio of 9.4x. Average forward P/E is 35x in the Biotechs industry in South Korea. Total returns to shareholders of 291% over the past three years.
Valuation Update With 7 Day Price Move • Jul 03Investor sentiment improved over the past weekAfter last week's 33% share price gain to ₩26,400, the stock trades at a trailing P/E ratio of 6.7x. Average forward P/E is 36x in the Biotechs industry in South Korea. Total returns to shareholders of 188% over the past three years.
分析記事 • Mar 25Bioneer (KOSDAQ:064550) Seems To Use Debt Quite SensiblyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩16,100, the stock is trading at a trailing P/E ratio of 18.2x, down from the previous P/E ratio of 21.4x. This compares to an average P/E of 54x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 36%.
分析記事 • Feb 15Bioneer Corporation's (KOSDAQ:064550) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?It is hard to get excited after looking at Bioneer's (KOSDAQ:064550) recent performance, when its stock has declined...
分析記事 • Jan 20Investors Who Bought Bioneer (KOSDAQ:064550) Shares A Year Ago Are Now Up 166%The last three months have been tough on Bioneer Corporation ( KOSDAQ:064550 ) shareholders, who have seen the share...
Valuation Update With 7 Day Price Move • Jan 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩18,600, the stock is trading at a trailing P/E ratio of 21x, up from the previous P/E ratio of 18x. This compares to an average P/E of 57x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 90%.
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩16,000, the stock is trading at a trailing P/E ratio of 18x, down from the previous P/E ratio of 21.4x. This compares to an average P/E of 55x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 78%.
分析記事 • Dec 24Is Bioneer (KOSDAQ:064550) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Is New 90 Day High Low • Dec 22New 90-day low: ₩17,650The company is down 33% from its price of ₩26,450 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 14% over the same period.
分析記事 • Nov 28Here's Why We Think Bioneer's (KOSDAQ:064550) Statutory Earnings Might Be ConservativeIt might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...
Is New 90 Day High Low • Nov 12New 90-day low: ₩21,100The company is down 1.0% from its price of ₩21,300 on 14 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 4.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 12Market pulls back on stock over the past weekAfter last week's 19% share price decline to ₩21,100, the stock is trading at a trailing P/E ratio of 29.7x, down from the previous P/E ratio of 36.7x. This compares to an average P/E of 69x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 153%.
Valuation Update With 7 Day Price Move • Oct 28Market pulls back on stock over the past weekAfter last week's 16% share price decline to ₩22,450, the stock is trading at a trailing P/E ratio of 31.6x, down from the previous P/E ratio of 37.8x. This compares to an average P/E of 58x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 172%.
